Interpretation of Resistance Assay Results

Carpenter C.C. , Cooper D.A. , Fischl M.A. , Gatell J.M. , Gazzard B.G. , Hammer S.M. , Hirsch M.S. , Jacobsen D.M. , Katzenstein D.A. , Montaner J.S. , Richman D.D. , Saag M.S. , Schechter M. , Schooley R.T. , Thompson M.A. , Vella S. , Yeni P.G. , & Volberding P.A. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283: 381–390.

Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://www.hivatis.org/guidelines/adult/pdf/A&ajani.pdf 28-1-2000. Last accessed 12-9-2000.

BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. http://www.aidsmap.com/2000. Last accessed 7-9-2000.

The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15: 309–320.

Flexner C. HIV genotype and phenotype – arresting resistance. Journal of the American Medical Association 2000; 283: 2442–2444.

Boden D. , Hurley A. , Zhang L. , Cao Y. , Guo Y. , Jones E. , Tsay J. , Ip J. , Farthing C. , Limoli K. , Parkin N. , & Markowitz M. HIV-1 drug resistance in newly infected individuals. Journal of the American Medical Association 1999; 282: 1135–1141.

Little S.J. , Daar E.S. , D'Aquila R.T. , Keiser P.H. , Connick E. , Whitcomb J.M. , Hellmann N.S. , Petropoulos C.J. , Sutton L. , Pitt J.A. , Rosenberg E.S. , Koup R.A. , Walker B.D. , & Richman D.D. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. Journal of the American Medical Association 1999; 282: 1142–1149.

Bonhoeffer S. Models of viral kinetics and drug resistance in HIV-1 infection. AIDS Patient Care STDs 1998; 12: 769–774.

Larder B. , De Vroey V. , Dehertogh P. , Kemp S. , Bloor S. , & Hertogs K. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Antiviral Therapy 1999; 4 (Suppl. 1): 41.

Baxter J.D. , Mayers D , & Wentworth D.N. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14: F83–F93.

Durant J. , Clevenburgh P. , Halfon P. , Delgiudice P. , Porsin S. , Simonet P. , Montagne N. , Boucher C.A. , Schapiro J.M. , & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195–2199.

De Luca A. , Antinori A. , Cingolani A. , Rizzo M.G. , Murri R. , Ammassari A. , Baldini F. , Di Giambenedetto S. , Marconi P. , Ciancio B. , & Cauda R. A prospective, randomized study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA): final 6-month results. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA, 4–8 February 2001; Abstract 433.

Cohen C. , Kessler H. , Hunt S. , Sension M. , Farthing C. , Conant M. , Jacobson S. , Nadler J. , Verbiest W. , Hertogs K. , Ames M. , Rinehart A. , & Graham N. Phenotypic resistance testing significantly improves response to therapy (Tx): analysis of a randomized trial (VIRA3001). XIII International AIDS Conference. Durban, South Africa, 9–14 July 2000; Abstract 1433.

Melnick D. , Rosenthal J. , Cameron M. , Snyder M. , Griffith-Howard S. , Hertogs K. , Verbiest W. , Graham N. , & Pham S. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, Calif., USA, 30 January – 2 February 2000; Abstract 786.

Meynard J.L. , Vray M. , Morand-Joubert L. , Matheron S. , Peytavin G. , Clavel F. , Brun-Vezinet F. , & Girard P.M. Impact of treatment guided by phenotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy 2000; 5 (Suppl. 3): 67–68.

Tural C. , Ruiz L. , Holtzer C. , Viciana P. , González J. , Ferrer E. , Martínez-Picado J. , Ruiz I. , Dalmau D. , Domingo P. , Been A. , Boucher C.A.B. , Schapiro J. , Romeu J. , Sirera G , & Clotet B. , & Havanna Study Group. Utility of HIV genotyping and clinical expert advice – the Havana Trial. Antiviral Therapy 2001; 6: S31.

Miller V. , Sabin C. , Hertogs K. , Bloor S. , Martinez-Picado J. , D'Aquila R. , Larder B. , Lutz T. , Gute P. , Weidmann E. , Rabenau H. , Phillips A. , & Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14: 2857–2867.

Devereux H.L. , Youle M. , Johnson M.A. , & Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123–F127.

Finzi D. , Hermankova M. , Pierson T. , Carruth L.M. , Buck C. , Chaisson R.E. , Quinn T.C. , Chadwick K. , Margolick J. , Brookmeyer R. , Gallant J. , Markowitz M. , Ho D.D. , Richman D.D. , & Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–1300.

Wong J.K. , Hezareh M. , Gunthard H. F. , Havlir D V. , Ignacio C.C. , Spina C.A. , & Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291–1295.

Günthard H.F. , Wong J.K. , Ignacio C.C. , Havlir D.V. , & Richman D.D. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Reserch and Human Retroviruses 1998; 14: 869–876.

Schuurman R. , Demeter L. , Reichelderfer P. , Tijnagel J. , de Groot T. , & Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Journal of Clinical Microbiology 1999; 37: 2291–2296.

Gurtler L.G. , Hauser P.H. , Eberle J. , von Brunn A. , Knapp S. , Zekeng L. , Tsague J.M. , & Kaptue L. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. Journal of Virology 1994; 68: 1581–1585.

Simon F. , Mauclere P. , Roques P. , Loussert-Ajaka I. , Muller-Trutwin M.C. , Saragosti S. , Georges-Courbot M.C. , Barre-Sinoussi F. , & Brun-Vezinet F. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nature Medicine 1998; 4: 1032–1037.

Robertson D.L. , Anderson J.P. , Bradac J.A. , Carr J.K. , Foley B. , Funkhouser R.K. , Gao F. , Hahn B.H. , Kalish M.L. , Kuiken C. , Learn G.H. , Leitner T. , McCutchan F. , Osmanov S. , Peeters M. , Pieniazek D. , Salminen M. , Sharp P.M. , Wolinsky S. , & Korber B. A reference guide to HIV-1 classification. http://hiv-web.lanl.gov/HTML/reviews/nomenclature/Nomen.html. 2000. Last accessed 7-9-2000.

Simon F. , Loussert-Ajaka I. , Damond F. , Saragosti S. , Barin F. , & Brun-Vezinet F. HIV type 1 diversity in northern Paris, France. AIDS Research and Human Retroviruses 1996; 12: 1427–1433.

Petropoulos C.J. , Parkin N.T. , Limoli K.L. , Lie Y.S. , Wrin T. , Huang W. , Tian H. , Smith D. , Winslow G.A. , Capon D.J. , & Whitcomb J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 2000; 44: 920–928.

de Bethune M.P. , Hertogs K. , Heyndrickx L. , Vingerhoets J. , Fransen K. , Azijn H. , Michiels L. , Janssens W. , Scholliers A. , Larder B. , Bloor S. , Pauwels R. , & van der Groen G. Does natural or acquired resistance to reverse transcriptase and protease inhibitors, observed in HIV-1 groups M (subtypes A–H) and O, differ from subtype B. Antiviral Therapy 1999; 4 (Suppl. 1): 33.

Qari S.H. , Respess R. , Weinstock H. , Beltrami E. , Hertogs K. , Larder B.A. , Petropoulos C.J. , Hellmann N. , & Heneine W. A comparative analysis of Virco Antivirogram and ViroLogic PhenoSense phenotypic assays for drug susceptibility of HIV-1. Antiviral Therapy 2000; 5 (Suppl. 3): 49.

Vingerhoets J. , Bloor S. , Michiels L. , Scholliers A. , Dehertogh P. , Van Den Eynde C. , De Vroey V. , Van Cauwenberge A. , de Koning I. , Alcorn T. , Larder B. , & Hertogs K. The accuracy and reproducibility of high-throughput genotypic and phenotypic HIV-1 resistance testing under EN45001 and CLIA accreditation labels. Antiviral Therapy 1999; 4 (Suppl. 1): 53.

Schuurman R. , Brambilla D. , de Groot T. , & Boucher C. Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel. Antiviral Therapy 1999; 4 (Suppl. 1): 41.

Hertogs K. , Zolopa A. , Bloor S. , Shafer B. , De Vroey V. , Warford A. , Larder B. , & Merigan T. A blinded comparative analysis of two genotyping service laboratories: full sequence analysis of HIV-1 protease and reverse transcriptase. Antiviral Therapy 1999; 4 (Suppl. 1): 59.

Collin G. , Descamps D. , Telles F. , Matheron S. , Obry V. , Costagliola D. , & Brun-Vézinet F. Differences in protease and reverse transcriptase sequences between the TruGene HIV-1 genotyping kit (Visible Genetics) and the ViroSeq genotyping system (PE Applied Biosystems). Antiviral Therapy 2000; 5 (Suppl. 3): 53.

Hertogs K. The role of phenotypic resistance testing in assessing treatment failure. Journal of HIV Therapy 2000; 5: 42–46.

Tisdale M. , Alnadaf T. , & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41: 1094–1098.

Rozenbaum W. , Katlama C. , Massip P. , Lanier R. , Mamet J.P. , & David F. Sustained immunological and virological response after two years of triple nucleoside therapy with ABC/3TC/ZDV in HIV-1 infected patients pretreated with 3TC/ZDV (CNA3009). 5th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 22–26 October 2000; Abstract 324.

Ait-Khaled M. , Rakik A. , Griffin P. , Gould J. , Cutrell A. , & Fischl M. and the CNA3003 International Study Group. Viral rebound during 48 weeks of ABC/3TC/ZDV combination therapy in antiretroviral-naive adults is infrequent with emergent virus showing a limited number of resistance mutations. Antiviral Therapy 1999; 4 (Suppl. 1): 52–53.

Fischl M.A. , Clumeck N. , Greenberg S.B. , Kumar P. , Hicks C.B. , Pulido F. , Peters B.S. , Rubio R. , Cutrell A. , Gould J. , Pearce G. , Spreen W. , Pobiner B. , & LaFon S for the CNA3003 International Study Team. A controlled trial of abacavir, lamivudine, and zidovudine in persons with human immunodeficiency virus infection and no prior antiretroviral therapy. Submitted 2000.

Henry K. , Wallace R.J. , Bellman P.C. , Norris D. , Fisher R.L. , Ross L.L. , Liao Q. , & Shaefer MS for the TARGET Study Team. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET study. Journal of Infectious Diseases 2001; 183: 571–578.

Kessler H. , Cohen C. , Sension M. , Farthing C. , Jacobson S. , Conant M. , Hertogs K. , Verbiest W. , Lanier R. , Rinehart A. , & Graham N. Response to abacavir-containing regimens is not affected by presence of pre-existing lamivudine resistance and is greater than response in non-abacavir-containing regimens in VIRA3001. Antiviral Therapy 2000; 5 (Suppl. 3): 95.

Ait-Khaled M. , Stone C. , Amphlett G. , Clotet B. , Staszewski S. , & Katlama C. Lamivudine as part of a first-line antiretroviral regimen significantly delays the acquisition of mutations associated with zidovudine and stavudine. Antiviral Therapy 2000; 5: 129–130.

Back N.K. , Nijhuis M. , Keulen W. , Boucher C.A. , Oude E.B. , van Kuilenburg A.B. , van Gennip A.H. , & Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. European Molecular Biology Organization Journal 1996; 15: 4040–4049.

Boyer P.L. , & Hughes S.H. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 1995; 39: 1624–1628.

Wainberg M.A. , Drosopoulos W.C. , Salomon H. , Hsu M. , Borkow G. , Parniak M. , Gu Z. , Song Q. , Manne J. , Islam S. , Castriota G. , & Prasad V.R. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271: 1282–1285.

Feng J.Y. , & Anderson K.S. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999; 38: 9440–9448.

Schmitt M. , Harrer E. , Goldwich A. , Bauerle M. , Graedner I. , Kalden J.R. , & Harrer T. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 2000; 14: 653–658.

Tian H. , Whitcomb J.H. , Limoli K. , Wrin T. , Winslow G. , Parkin N. , Smith D. , Lie Y.S. , Bakthiari M. , Shugarts D. , Schooley R.T. , Kuritzkes D. , & Petropoulos C.J. Zidovudine/lamivudine co-resistance is preceded by a transient period of zidovudine hypersensitivity. Antiviral Therapy 1998; 3(Suppl. 1): 22–23.

Wainberg M.A. , Miller M.D. , Quan Y. , Salomon H. , Mulato A.S. , Lamy P.D. , Margot N.A. , Anton K.E. , & Cherrington J.M. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4: 87–94.

Moyle G.J. , & Gazzard B.G. Differing reverse transcriptase mutation patterns in persons experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine. Antiviral Therapy 2000; 5 (Suppl. 3): 22.

Calvez V. , Mouroux M. , Descamps D. , Izopet J. , Delaugerre C. , Yvon A. , Matheron S. , Simon A. , Valantin M-A , Bonmarchand M. , Agut H. , Massip P. , Brun-Vezinet F. , & Katlama C. Occurrence of thymidine-associated mutations in naïve patients treated more than 6 months by stavudine/lamivudine bitherapy combination and tri-therapies including stavudine/didanosine or stavudine/lamivudine. Antiviral Therapy 2000; 5 (Suppl. 3): 40–41.

Deeks S.G. , & Zolopa A.R. Choosing and using resistance assays. http://www.medscape.com/medscape/HIV/AnnualUpdate/2000/mha.update05.06.deeks/mha05.deeks-01.html 2000. Last accessed 8-2-2001.

Martinez-Picado J. , Sutton L. , De Pasquale M.P. , Savara A.V. , & D'Aquila R.T. Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. Journal of Clinical Microbiology 1999; 37: 2943–2951.

Hirsch M.S. , Brun-Vezinet F. , D'Aquila R.T. , Hammer S.M. , Johnson V.A. , Kuritzkes D.R. , Loveday C. , Mellors J.W. , Clotet B. , Conway B. , Demeter L.M. , Vella S. , Jacobsen D.M. , & Richman D.D. Antiretroviral drug resistance testing in adult with HIV infection. Recommendations of an International AIDS Society-USA Panel. Journal of the American Medical Association 2000; 283: 2417–2426.

De Luca A. , Cingolani A. , Rizzo M.G. , Murri R. , Di Giambenedetto S. , Baldini F. , Ammassari A. , & Antinori A. Prediction of treatment outcomes by different interpretation systems (IS) for baseline genotypic resistance in a cohort of patients on salvage HIV therapy. Antiviral Therapy 2001; 6: S33.

Calvez V. , Costagliola D. , Descamps D. , Matheron S. , Simon A. , Valantin M-A , Katlama C. , & Brun-Vezinet F. Resistance and viral response to stavudine/lamivudine combination in zidovudine experienced patients in the ALTIS-2 ANRS trial. Antiviral Therapy 2000; 5 (Suppl. 3): 83.

Lanier E.R. , Melby M.H. , St Clair M.H. , Thorborn D. , Pearce G. , Hetherington S. , Smiley L. , & Lafon S. Potential clinical impact of small differences between VIRCO Antivirogram and ViroLogic Phenosense assays for abacavir in 3TC experienced patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, Calif., USA, 30 January – 2 February 2000; Abstract 788.

Larder B.A. , & Harrigan P.R. Establishment of biologically relevant cut-offs for HIV drug resistance testing. 5th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 22–26 October 2000; Abstract P327.

Lanier E.R. , Hellman N. , Scott J. , Ait-Khaled M. , Melby T. , Carsanaro J. , Petropoulos C. , Kusaba E. , Smiley L. , & Lafon S. Determination of a clinically relevant phenotypic resistance ‘cutoff’ for abacavir using the PhenoSense™ assay. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., USA, 4–8 February 2001; Abstract 254.

Haubrich R. The effects of different phenotypic cut-points using ViroLogics assay: towards clinically relevant phenotypic cut-off values for NRTIs. 3rd European Symposium on the Clinical Implications of HIV Drug Resistance. Frankfurt, Germany, 23–25 February 2001; Abstract Satellite symposium 1.

Zolopa A.R. , Shafer R.W. , Warford A. , Montoya J.G. , Hsu P. , Katzenstein D. , Merigan T.C. , & Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine 1999; 131: 813–821.

Vandamme A.M. , Houyez F. , Bànhegyi D. , Clotet B. , De Schrijver G. , De Smet K.A.L. , Hall W. W. , Harrigan R. , Hellmann N. , Hertogs K. , Holtzer C. , Larder B. , Pllay D. , Race E. , Schmit J.C. , Schuurman R. , Shulse E. , Sönnerborg A. , & Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Therapy 2001; 6: 21–39.

National Pediatric and Family HIV Resource Center (NPHRC). Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://www.hivatis.org/guidelines/Pediatric/Text/ped_12.pdf 7-1-2000. Last accessed 15-2-2001.